Breaking Headlines

Category archive

Health

BREAKING: Direct Relief Makes $32 Million in Medical Inventories Available to Colombia and Peru amid Historic Flooding

in advocacy/BREAKING NEWS/charity/food/Health/healthcare/international/medical/medicine/non profit/organizations/poverty/Relief Effort by
Reading Time: 2 minutes

$200,000 Initial Cash Committed for Relief Effort, FedEx and Healthcare Companies Step Up as Emergency Unfolds

GOLETA, Calif., April 6, 2017 /360WiseNews/ — Direct Relief today committed an initial $200,000 in cash and made available $32 million in medical resources for relief and recovery efforts in Colombia and Peru, where historic flooding and mudslides have claimed hundreds of lives and displaced hundreds of thousands more.

Today’s commitment follows several emergency air shipments from Direct Relief of medical aid totaling $7.8 million and 38 tons (76,000 lbs.).

“People in Peru and Colombia are facing severe risks in the wake of devastating storms, and Direct Relief is extending support to our capable partner organizations providing frontline care in a still unfolding, complex emergency,” said Direct Relief President and CEO Thomas Tighe.

Water sources often become compromised after serious flooding, which can lead to a host of health issues. Cholera and other diseases related to poor sanitation pose additional threats to public health. Neglected tropical diseases including trachoma, soil-transmitted pathogens, and various bacterial and parasitic infections also present risks to people in the area.

Bolstered by strong support from corporate partners that include AbbVie, Allergan, Actavis, Baxter, BD, Boehringer Ingelheim, Teva, Pfizer, and Unilever, Direct Relief is sending antibiotics, antivirals, rehydration supplies and hygiene kits. FedEx has provided emergency airlift support.

In Peru, Direct Relief is assisting four partner organizations providing emergency services and conducting medical missions in close coordination with the Peruvian Ministry of Health. Patrulla Area Colombiana (PAC, a Colombian NGO of pilots and medics), Asociacion Paz Peru, Socios en Salud (Partners in Health), and Asociacion Vida Peru have received and distributed $3.9 million of essential medications and supplies totaling 17.5 tons to eight hard-hit regions: Lima, Huarmey, Piura, Pedregal Alto, Simbila, Tumbes, Casma, and Arequipa. Direct Relief also is funding the deployment of 20 medical personnel to Piura to provide medical care and deliver seven tons of medicine and medical supplies. Keep Reading

BREAKING:Rehab Equipment Market by Type (Mobility (Wheelchair, Assist Device), Body Support (Lift, Sling), Exercise (Upper, Lower Body), Living Aids (Reading, Writing)), Application (Physiotherapy, OT), End User (Hospital, Clinic, Home Care) – Forecasts to 2021

in BREAKING NEWS/Health/healthcare/medical/mobility/rehab equipment/Technology/wheelchair by
Reading Time: 3 minutes

NEW YORK, April 6, 2017 /360WiseNews/ — The rehabilitation equipment market is projected to reach USD 14.91 billion by 2021 from USD 9.86 billion in 2016, at a CAGR of 8.6% during 2016-2021. The market for rehabilitation equipment is expanding due to the increasing incidence of disabilities resulting from non-communicable diseases, favorable healthcare reforms, and rapid growth in the geriatric population, coupled with the rising prevalence of chronic diseases. On the other hand, the high cost & maintenance expense of rehabilitation equipment are limiting the growth of the market to a certain extent.

Read the full report: http://www.reportlinker.com/p04814913/Rehab-Equipment-Market-by-Type-Mobility-Wheelchair-Assist-Device-Body-Support-Lift-Sling-Exercise-Upper-Lower-Body-Living-Aids-Reading-Writing-Application-Physiotherapy-OT-End-User-Hospital-Clinic-Home-Care-Forecasts-to.html

Based on type, the rehabilitation equipment market is segmented mobility equipment, body support devices, exercise equipment, and daily living aids. The mobility equipment segment is expected to grow at the highest CAGR during 2016–2021. The growth in this segment is attributed to the increasing the number of elderly people suffering from orthopedic impairments which is creating a demand for mobility equipment worldwide. Moreover, the increasing number of disabled people and growing awareness on safety measures in handling patients are driving the demand for mobility equipment. Keep Reading

BREAKING: Non-Invasive Prenatal Testing (NIPT) Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) – Global Forecast to 2021

in Baby's/BREAKING NEWS/children/fetal/Health/medical/prenatal testing market/research/Technology/Women by
Reading Time: 3 minutes

NEW YORK, April 6, 2017 /360WiseNews/ —

The global non-invasive prenatal testing (NIPT) market is projected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016, at a CAGR of 16.4% from 2016 to 2021.

The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period.

Read the full report: http://www.reportlinker.com/p04814911/Non-Invasive-Prenatal-Testing-NIPT-Market-by-Instruments-Ultrasound-NGS-PCR-Microarray-Consumables-Method-FCMB-cf-DNA-Application-Trisomy-Microdeletion-Genetics-Rh-factor-End-User-Hospital-Diagnostic-Labs-Global-Forecast-to.html

By product, the non-invasive prenatal testing market is segmented into consumables and instruments. In 2016, the consumables segment accounted for the largest share of the market. The high demand due to the recurring requirement of consumables as compared to instruments is a key driver for the growth of this product segment.

On the basis of method, the market is segmented into ultrasound detection, biochemical screening tests, fetal cells in maternal blood tests, and cell-free DNA in maternal plasma tests. The ultrasound detection segment dominated the market in 2016. However, the cell-free DNA in maternal plasma tests segment is expected to grow at the highest CAGR. This is mainly attributed to the increasing demand for cf-DNA based techniques in NIPT testing and rising government initiatives to provide prenatal services.

On the basis of application, the market is segmented into Trisomy, microdeletion syndrome, and other applications. Trisomy commands the largest and fastest-growing application segment of the global market in 2016. This is attributed to factors such as increasing maternal age and rising incidence of chromosomal abnormalities. Keep Reading

BREAKING: Drugs of Abuse Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024

in drug abuse/Health/market revenue/research by
Reading Time: 3 minutes

NEW YORK, April 6, 2017 /360WiseNews/ — Global Drugs of Abuse Testing Market: Scope and Methodology

This report on the global drugs of abuse testing market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

Read the full report: http://www.reportlinker.com/p04589986/Drugs-of-Abuse-Testing-Market-Global-Industry-Analysis-Size-Share-Growth-Trends-and-Forecast.html

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2015 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global drugs of abuse testing market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global drugs of abuse testing market. Keep Reading

Body Weight Fluctuations Linked to More Deaths in People with Coronary Artery Disease

in BREAKING NEWS/cardiac/Health/medical by
Reading Time: 3 minutes

NEW YORK, April 5, 2017 /360WiseNews/ — Repeated cycles of weight loss and gain may be linked to higher risk for stroke, heart attack, and death in people with pre-existing coronary artery disease, according to a study published online April, 5 in the New England Journal of Medicine.

Led by researchers at NYU Langone Medical Center, the study was the first to measure the effect of “weight cycling” on health outcomes in people with pre-existing heart disease. People with the largest weight changes were found to experience 136 percent more strokes, 117 percent more heart attacks, and 124 percent more deaths than those with the smallest shifts in weight.

Those in the high-fluctuation group had weight changes as large as 3.9 kilograms (or roughly 8.6 pounds), while weight varied by around 0.9 kilograms (just under 2 pounds) in the group with the smallest shifts in weight.

“Our findings suggest that we need to be concerned about weight fluctuation in this group that is already at high risk due to coronary disease,” says lead study author Sripal Bangalore, MD, director of the cardiovascular outcomes group in the Cardiovascular Clinical Research Center at NYU Langone.

“Even though this analysis was not designed to find out the causes of increased risk with body weight fluctuations, we need to examine how we can help Americans keep weight off, rather than having it go up and down,” says Bangalore, an associate professor of medicine in the Leon H. Charney Division of Cardiology. Keep Reading

OMRON to Introduce E5CD/E5ED Temperature Controllers Which Automatically Adjust Temperature like Skilled Workers Using AI for Production Sites, First Time in Industry (*)

in BREAKING NEWS/Business and Finance/Digital/Health/medical/Press Release/Technology/temperature by
Reading Time: 3 minutes

KYOTO, Japan, March 30, 2017 /360WiseNews/ — OMRON Corporation (TSE: 6645, ADR: OMRNY) will introduce on April 3, 2017, “E5CD/E5ED Temperature Controllers” to automatically adjust temperature parameters of heaters and others using AI that used to be done by skilled workers at production sites and “E52-CA xx AY S xx Temperature Sensors for Packaging Machines.”

OMRON will showcase the “E5CD/E5ED Temperature Controllers” and “E52-CA xx AY S xx Temperature Sensors for Packaging Machines” at the “2017 International Food Machinery & Technology Exhibition” to be held at Tokyo Big Sight from June 13 to 16.

(Photo1: E5CD/E5ED Temperature Controllers
http://prw.kyodonews.jp/prwfile/release/M102197/201703230211/_prw_PI1fl_2ZobErLL.png)

(Photo2: E52-CA xx AY S xx Temperature Sensors for Packaging Machines
http://prw.kyodonews.jp/prwfile/release/M102197/201703230211/_prw_PI2fl_JO25x72o.png)

The newly released E5CD/E5ED Temperature Controllers include OMRON’s unique temperature adjustment algorithm. The E5CD and E5ED automatically adjust temperature parameters that until now skilled workers have been doing based on experience and intuition in response to production status changes, including production items and materials compounding.

At today’s production sites, multi-product production makes manufacturing highly complicated. This accelerates production transfer to emerging countries for optimally located production, leading to product defects and lower productivity resulting from worker skill shortage. Especially in the molding and packaging processes, temperature adjustment required when production items change is not properly done. To avoid quality loss that is caused by temperature, the equipment operation speed slows down and inspection work takes more time at the expense of productivity. Keep Reading

GHIT Fund Invests in Late-stage Trial for Child-friendly “Snail Fever” Medicines–One of the Most Debilitating and Widespread Parasitic Diseases in Africa

in BREAKING NEWS/children/Health/medicine by
Reading Time: 7 minutes

Completion of Phase 3 trial for treatment of “Snail Fever” (aka schistosomiasis) is final step before regulatory and WHO submission; GHIT also announces new investment in novel malaria vaccine and therapeutic for dengue, continued support for innovative tools to tackle malaria and neglected tropical diseases

TOKYO, March 30, 2017 /360WiseNews/ — The Global Health Innovative Technology Fund (GHIT Fund), a unique Japanese public-private partnership formed to battle infectious diseases around the globe, today announced 11 new investments totaling US$23 million* that could help deliver a range of new innovative therapies for a host of debilitating conditions.

This latest round of targeted support includes funding for a Phase 3 clinical trial testing a pediatric formulation of a drug considered the gold standard for treating schistosomiasis, a water-borne parasitic disease linked to an assortment of acute and chronic health problems. Young children are most at risk, but the existing drug is so bitter and hard to swallow that kids often go untreated, leading to serious lifelong health and learning problems.

This clinical trial is one of the most advanced partnerships invested by the GHIT Fund, an organization that combines Japan’s historic leadership in global health and innovation with groundbreaking research from across the globe. The GHIT Fund also is making new investments in two malaria vaccine candidates, while accelerating work to find new drug treatments for malaria, dengue, Chagas disease, cryptosporidiosis and leishmaniasis.

“We’re reaching an exciting phase where GHIT’s approach to partnerships and drug and vaccine development is starting to produce tangible progress towards product deployment that could eventually lead to revolutionary breakthroughs,” said BT Slingsby, MD, PhD, MPH, who is CEO of the GHIT Fund. “We knew that combining Japan’s wealth of biomedical research talent and pharmaceutical capabilities with leading infectious disease experts near and far was likely to be a winning combination, and that’s been validated by the progress we are seeing across a rich diversity of projects.”

A Snail Fever Drug That’s Easy to Swallow

Schistosomiasis, sometimes called “snail fever” because it’s found in freshwater snails, leads to both acute and chronic disease. It’s caused by parasitic worms known as blood flukes and is usually transmitted through contact with infested water. The disease is endemic in 78 developing countries and, according to the World Health Organization, more than 261 million people, including 100 million children, were infected with schistosomiasis in 2015. Some 90 percent of infections occur in Africa, where safe water is often scarce. While rarely fatal, left untreated, the disease can cause anemia, stunted growth, impaired learning ability and chronic inflammation of vital organs.

GHIT Fund’s investment of US$4.7 million, with co-funding from its partners, will support a Phase 3 clinical trial in Africa to evaluate a pediatric formulation of praziquantel (PZQ) in children aged three months to six years. Since the 1970s, the gold-standard of treatment for the disease has been a single oral dose of PZQ used to treat adults and school-aged children. But children under age five who are infected with schistosomiasis are not treated with PZQ under the current policy. And data on the treatment of these children has been sparse and insufficient to define and confirm the best dosing. In addition, the current tablets have a severe bitter taste and the large size of the existing pill makes it difficult or just impossible for small children to swallow. A smaller, more palatable pill that could be administered to children as young as three months old is being developed by the Pediatric Praziquantel Consortium, a nonprofit international public-private partnership involving Astellas Pharma Inc. (Japan), Lygature (The Netherlands), Merck KGaA (Germany), the Swiss Tropical and Public Health Institute, Simcyp Limited (UK), Farmanguinhos (Brazil) and the Schistosomiasis Control Initiative (SCI, UK). Keep Reading

Family Fights to Stop Hewlett Packard and Insurer From Cutting Off Healthcare that Saves Father’s Life, According to Federal Lawsuit by Jonathan Davidson Law Firm

in Health/Insurance/lawsuits by
Reading Time: 2 minutes

RIVERSIDE, Calif., March 30, 2017 /360WiseNews/ — According to a lawsuit filed in the federal District Court in the Northern District of California in San Jose, the experience of one patient, Jonathan Davidson, puts a spotlight on the large companies Hewlett Packard Enterprise and United HealthCare seeking to manipulate healthcare payment systems by cutting off a patient’s life-saving care, as alleged in the lawsuit in which Mr. Davidson’s Jonathan Davidson Law Firm is representing him. Hewlett Packard Enterprise (HP) plans a merger this week with another giant computer services company, Computer Sciences Corporation, which has repeatedly been charged with systematically engaging in false or fraudulent practices in its business with Medicaid, the British National Health Service and others. In the merger, 120,000 or so HP employees are set to be “spun off” into a newly created HP-CSC merger company called “DXC Technology,” with their prior HP sponsored health plan replaced by a “private exchange model” adopted for its “lower cost structure” for HP.

According to Jonathan Davidson, his case exemplifies the abuses that victimize millions of ill patients, including employees and others with company or group medical coverage, and also the public and taxpayers through inflated medical and health insurance costs. Keep Reading

Medical Ceramics Market is Expected to Reach $5,841 Million by 2022, Globally-Allied Market Research

in BREAKING NEWS/Business and Finance/Health/medical ceramics/medicine/organizations/Press Release by
Reading Time: 3 minutes

PORTLAND, Oregon and PUNE, India, March 15, 2017 /360WiseNews/ —

A new report published by Allied Market Research titled, Medical Ceramics Global Opportunity Analysis and Industry Forecast, 20142022“, projects that the global medical ceramics market was valued at $3,850 million in 2015, and is expected to reach $5,841 million by 2022, registering a CAGR of 6.2% from 2016 to 2022. Implants segment is expected to remain the highest revenue contributor throughout the forecast period. U.S. held the leading position in the global market in 2015, and is expected to maintain its lead throughout the study period.

 

Summary of the Medical Ceramics Market can be accessed on the website at:https://www.alliedmarketresearch.com/medical-ceramics-market

According to Eswara Prasad, Team Lead Chemical Research at Allied Market Research, Medical ceramics are widely preferred in dentistry due to their large compressive and load bearing capacity and similarity with dental materials such as enamel.

The upsurge in the demand for medical ceramics from medical device industry creates attractive opportunities for market growth. Properties of medical ceramics such as high compressive strength and biodegradability, which are necessary for bone implants are leading market growth. Medical ceramics minimize bone ingrowth, which is a key factor boosting its adoption in the market. Growth in applications of medical ceramics for inartificial total hip, knee, shoulder, elbow, wrist; bone plates, screws, wires; intramedullary nails; permanently implanted artificial limbs; spinal fusion; alveolar bone replacements, mandibular reconstruction; and tooth replacement implants has opened new growth avenues for medical ceramics market. Growth in ceramic implants market has also fueled the demand for medical ceramics as it can be framed to match the material properties of a natural bone.

The application of the medical ceramics in the implants segments holds highest share in 2015 and is expected to maintain its lead throughout the forecast period. The increase in use of ceramics as rigid materials to manufacture implants is due to absence of prosthetics, thus reducing the risk of bacterial growth. Zirconia and alumina are the most commonly used ceramic materials used to develop implants. Zirconia, a type of bio-inert ceramic is expected to be the fastest growing segment in the global medical ceramics market followed by piezo ceramics. Ceramics are preferred for orthopedic implants by manufacturers due to their high resistance and biochemical inertness. Alumina is the most commonly used ceramic utilized for manufacturing orthopedic implants. Keep Reading

Global Atopic Dermatitis Drugs Market 2017-2021

in BREAKING NEWS/dermatitis/disease/Health/medicine/public relations/research market by
Reading Time: 2 minutes

NEW YORK, March 7, 2017 /360WiseNews/ — Atopic Dermatitis Drugs

Atopic dermatitis is a common, chronic, relapsing, inflammatory disease that primarily affects young children. Atopy refers to an inherited tendency to produce IgE antibodies, whereas, dermatitis means inflammation of the skin. Atopic dermatitis is associated with asthma, inhalant allergies (hay fever), and chronic dermatitis. In this condition, the skin becomes extremely itchy and inflamed, which causes redness, cracking, weeping, swelling, vesicle formation, crushing, and scaling. Atopic dermatitis is very common worldwide, and its prevalence rate is increasing. The data estimates suggest that nearly 60% of the patients develop symptoms in the first year of life, and 88%-92% develop symptoms before the age of five.

Technavio’s analysts forecast the global atopic dermatitis drugs market to grow at a CAGR of 4.20% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global atopic dermatitis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of atopic dermatitis drugs.

The market is divided into the following segments based on geography:
– Americas
– APAC
– EMEA

Technavio’s report, Global Atopic Dermatitis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Keep Reading

1 2 3 4
Go to Top